WO2005014032B1 - Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite - Google Patents
Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetiteInfo
- Publication number
- WO2005014032B1 WO2005014032B1 PCT/DK2004/000529 DK2004000529W WO2005014032B1 WO 2005014032 B1 WO2005014032 B1 WO 2005014032B1 DK 2004000529 W DK2004000529 W DK 2004000529W WO 2005014032 B1 WO2005014032 B1 WO 2005014032B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ghrelin
- use according
- acyl group
- compound
- medicament
- Prior art date
Links
- 206010006895 Cachexia Diseases 0.000 title claims abstract 10
- 230000000580 secretagogue effect Effects 0.000 title claims abstract 3
- 102000012004 Ghrelin Human genes 0.000 title claims 18
- 101800001586 Ghrelin Proteins 0.000 title claims 18
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 title claims 18
- 230000036528 appetite Effects 0.000 title 1
- 235000019789 appetite Nutrition 0.000 title 1
- 230000004936 stimulating effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 26
- 239000003814 drug Substances 0.000 claims abstract 21
- 238000011282 treatment Methods 0.000 claims abstract 10
- 150000003839 salts Chemical class 0.000 claims abstract 9
- 238000007920 subcutaneous administration Methods 0.000 claims abstract 5
- 230000007943 positive regulation of appetite Effects 0.000 claims abstract 4
- 238000011321 prophylaxis Methods 0.000 claims abstract 3
- 125000002252 acyl group Chemical group 0.000 claims 23
- 150000001413 amino acids Chemical class 0.000 claims 19
- 235000012054 meals Nutrition 0.000 claims 13
- 230000037396 body weight Effects 0.000 claims 11
- 238000000034 method Methods 0.000 claims 7
- 238000009472 formulation Methods 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 235000014113 dietary fatty acids Nutrition 0.000 claims 4
- 229930195729 fatty acid Natural products 0.000 claims 4
- 239000000194 fatty acid Substances 0.000 claims 4
- 150000004665 fatty acids Chemical class 0.000 claims 4
- 125000006239 protecting group Chemical group 0.000 claims 4
- 239000002904 solvent Substances 0.000 claims 4
- 230000000638 stimulation Effects 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 125000001165 hydrophobic group Chemical group 0.000 claims 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 210000000577 adipose tissue Anatomy 0.000 claims 2
- 230000000118 anti-neoplastic effect Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 238000012423 maintenance Methods 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 230000004584 weight gain Effects 0.000 claims 2
- 235000019786 weight gain Nutrition 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 101800004746 Ghrelin-24 Proteins 0.000 claims 1
- 206010049287 Lipodystrophy acquired Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 230000001539 anorectic effect Effects 0.000 claims 1
- 230000001925 catabolic effect Effects 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 235000013305 food Nutrition 0.000 claims 1
- 230000037406 food intake Effects 0.000 claims 1
- 235000012631 food intake Nutrition 0.000 claims 1
- 208000006132 lipodystrophy Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4745—Insulin-like growth factor binding protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Nutrition Science (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006522237A JP2007523048A (en) | 2003-08-06 | 2004-08-06 | Use of secretagogues |
US10/567,406 US20070037751A1 (en) | 2003-08-06 | 2004-08-06 | Uses of secretagogues like ghrelin in cancer cachexia and for stimulating appetite |
EP04739026A EP1660117A2 (en) | 2003-08-06 | 2004-08-06 | Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite |
Applications Claiming Priority (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200301139 | 2003-08-06 | ||
DKPA200301139 | 2003-08-06 | ||
DKPA200301140 | 2003-08-06 | ||
DKPA200301140 | 2003-08-06 | ||
US49481503P | 2003-08-14 | 2003-08-14 | |
US49481603P | 2003-08-14 | 2003-08-14 | |
US60/494,816 | 2003-08-14 | ||
US60/494,815 | 2003-08-14 | ||
DKPA200301283 | 2003-09-05 | ||
DKPA200301283 | 2003-09-05 | ||
DKPA200301570 | 2003-10-24 | ||
DKPA200301570 | 2003-10-24 | ||
DKPA200301569 | 2003-10-24 | ||
DKPA200301569 | 2003-10-24 | ||
DKPA200400570 | 2004-04-07 | ||
DKPA200400570 | 2004-04-07 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2005014032A2 WO2005014032A2 (en) | 2005-02-17 |
WO2005014032A3 WO2005014032A3 (en) | 2005-03-17 |
WO2005014032B1 true WO2005014032B1 (en) | 2005-04-28 |
Family
ID=34139992
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DK2004/000529 WO2005014032A2 (en) | 2003-08-06 | 2004-08-06 | Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1660117A2 (en) |
JP (1) | JP2007523048A (en) |
WO (1) | WO2005014032A2 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005097174A2 (en) * | 2004-04-07 | 2005-10-20 | Gastrotech Pharma A/S | Uses of a combination of ghrelin and somatotropin for the treatment of cachexia |
US20080171700A1 (en) * | 2004-04-07 | 2008-07-17 | Gastrotech Pharma A/S | Use Of Secretagogue For The Teatment Of Ghrelin Deficiency |
KR20070050871A (en) * | 2004-05-11 | 2007-05-16 | 더 거번먼트 오브 더 유나이티드 스테이츠 오브 어메리카 애즈 레프리젠티드 바이 더 세크러터리 오브 더 디파트먼트 오브 헬쓰 앤드 휴먼 써비시즈 | Methods of inhibiting proinflammatory cytokine expression using ghrelin |
EP1781311A4 (en) * | 2004-08-18 | 2010-02-17 | Elixir Pharmaceuticals Inc | Growth-hormone secretagogues |
WO2006045314A2 (en) * | 2004-10-27 | 2006-05-04 | Gastrotech Pharma A/S | Use of a growth hormone secretatogue for increasing or maintaining lean body mass and/or for treatment of chronic obstructive pulmonary disease |
WO2006045319A2 (en) * | 2004-10-27 | 2006-05-04 | Gastrotech Pharma A/S | Uses of growth hormone secretagogues in the treatment of individuals suffering from renal and/or liver failure |
WO2006045313A2 (en) * | 2004-10-27 | 2006-05-04 | Gastrotech Pharma A/S | Uses of secretagogues for treatment of organ transplant patients |
CA2645844C (en) * | 2006-03-13 | 2016-04-26 | Liat Mintz | Use of ghrelin splice variant for treating cachexia and/or anorexia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite-stimulation |
US7763707B2 (en) * | 2006-03-13 | 2010-07-27 | Liat Mintz | Use of ghrelin splice variant for treating cachexia and/or anorexia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite-stimulation |
ES2599168T3 (en) * | 2010-01-15 | 2017-01-31 | University Of Miyazaki | Ghrelin to promote the recovery of an animal under medical treatment |
US9486503B2 (en) | 2012-10-04 | 2016-11-08 | Shionogi & Co., Ltd. | Medicinal agent for suppressing malignant tumor metastasis |
AP2017009772A0 (en) | 2014-09-04 | 2017-02-28 | Helsinn Healthcare Sa | Medical treatments based on anamorelin |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04177224A (en) * | 1990-11-09 | 1992-06-24 | Sharp Corp | Liquid crystal display device |
US5798337A (en) * | 1994-11-16 | 1998-08-25 | Genentech, Inc. | Low molecular weight peptidomimetic growth hormone secretagogues |
AU2001228325A1 (en) * | 2000-02-01 | 2001-08-14 | Novo-Nordisk A/S | Use of compounds for the regulation of food intake |
JP2004514651A (en) * | 2000-05-30 | 2004-05-20 | メルク エンド カムパニー インコーポレーテッド | Ghrelin analogs |
IL145106A0 (en) * | 2000-08-30 | 2002-06-30 | Pfizer Prod Inc | Intermittent administration of a geowth hormone secretagogue |
-
2004
- 2004-08-06 WO PCT/DK2004/000529 patent/WO2005014032A2/en active Application Filing
- 2004-08-06 EP EP04739026A patent/EP1660117A2/en not_active Withdrawn
- 2004-08-06 JP JP2006522237A patent/JP2007523048A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2005014032A3 (en) | 2005-03-17 |
EP1660117A2 (en) | 2006-05-31 |
JP2007523048A (en) | 2007-08-16 |
WO2005014032A2 (en) | 2005-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070149476A1 (en) | Combination Comprising Combretastatin and Anticancer Agents | |
WO2005014032B1 (en) | Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite | |
US20040259834A1 (en) | Therapeutic composition containing at least diflomotecan and capecitabine | |
US4221784A (en) | Process and composition for treating disorders by administering lecithin | |
JP4824235B2 (en) | Drugs that protect against oxidative toxic substances, especially cardiotoxic substances | |
JP2000514415A (en) | Combination of somatostatin analog and rapamycin | |
US5888980A (en) | Compositions for enhancing immune function | |
EP2230908A1 (en) | Treatment of melanoma with alpha thymosin peptides in combination with an antineoplastic heat shock apoptosis activator (hsaa) | |
JP2706371B2 (en) | Auxiliary agent for cancer treatment and kit using the same | |
EP1784190A1 (en) | Substituted purinyl derivatives with immunomodulator and chemoprotective activity and use alone or with medium-chain length fatty acids or glycerides | |
JPH04305535A (en) | Combination of therapeutic active substances having cell proliferation inhibiting action or cytotoxicic action | |
US4321260A (en) | Method of using gonadorelin for the treatment of benign prostatic hyperplasia | |
JP3848537B2 (en) | Doramectin formulation | |
US5908824A (en) | Nasally administrable compositions containing physiologically active peptides | |
FR2609893A1 (en) | COMPOSITION BASED ON AMINO ACIDS AND VITAMINS FOR USE IN CANCEROLOGICAL THERAPEUTICS | |
MXPA02000915A (en) | Compositions containing muscle-derived active agents. | |
JP2004517821A (en) | Combinations of camptothecin and stilbene derivatives for cancer treatment | |
WO1999015174A1 (en) | Reverse prenyl compounds as immunosuppressants | |
NZ525623A (en) | Pharmaceutical composition containing gaba analogs and an antiviral agent to treat shingles | |
CN112533605A (en) | Combination therapy for the treatment of cancer | |
KR100499691B1 (en) | Anti-cancer pharmaceutical composition containing taxol and red ginseng acidic poly saccarride | |
KR101118778B1 (en) | Use of Ginkgo Biloba Extracts in order to Promote Muscle Mass to the Detriment of Fatty Mass | |
GB2189703A (en) | Vinpocetine | |
EP0547234A1 (en) | Remedy for osteoporosis | |
Mufazalova et al. | Effects of T-activin and vitamin E on toxicity and antitumor activity of cyclophosphamide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480029235.8 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
B | Later publication of amended claims |
Effective date: 20050314 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006522237 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004739026 Country of ref document: EP Ref document number: 784/CHENP/2006 Country of ref document: IN |
|
WWP | Wipo information: published in national office |
Ref document number: 2004739026 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007037751 Country of ref document: US Ref document number: 10567406 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10567406 Country of ref document: US |